New drug aims to save heart muscle after severe attack
NCT ID NCT06465303
First seen Oct 31, 2025 · Last updated May 01, 2026 · Updated 27 times
Summary
This study tests an experimental drug called RTP-026 in people who have had a severe type of heart attack (STEMI). The goal is to see if the drug can reduce heart muscle damage when given alongside standard emergency treatment. About 96 adults will receive either the drug or a placebo, and researchers will measure heart damage markers in the blood. The study is in Phase 2, meaning it is still early and focused on safety and initial effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ST ELEVATION MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hjertecenteret, Rigshospitalet
RECRUITINGCopenhagen, 2100, Denmark
Contact
Conditions
Explore the condition pages connected to this study.